The nonimmunotherapy-treated SWI/SNF-altered pancreatic cancer patients harbored 5 ARID1A alterations (83%) and 1 SMARCA4 mutation (17%); none possessed more than 1 SWI/SNF complex alteration. Here, SMARCA1 is linked to pancreatic neoplasm.